National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 16 of 2004)

Overview

The National Health Act 1953 was enacted to provide a framework for the delivery of health services in Australia, addressing the need for a coordinated approach to public health and healthcare funding. This Act was introduced by the Commonwealth Parliament to establish the National Health Service and to provide for the payment of benefits for medical, hospital, and pharmaceutical services. The specific legislative instrument, F2007B00632, is a declaration made under subsection 85(2AA) of the National Health Act 1953. It was issued by Joan Corbett, the Assistant Secretary of the Pharmaceutical Benefits Branch and Delegate of the Minister for Health and Ageing, on 17 November 2004, and it came into effect on 1 December 2004. The policy objective of this declaration was to cease the application of Part VII of the National Health Act 1953 to certain specified drugs and medicinal preparations, thereby removing them from the list of items eligible for pharmaceutical benefits. This was achieved by obtaining advice from the Pharmaceutical Benefits Advisory Committee as required by the Act.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to the specified drugs and medicinal preparations listed in the Schedule, which includes Ammonium Chloride, Bendrofluazide, Omeprazole Magnesium and Clarithromycin and Amoxycillin Trihydrate, Rofecoxib, Sodium Nitroprusside, and Timolol Maleate with Pilocarpine Hydrochloride. These drugs, effective from the commencement date of 1 December 2004, cease to be covered by Part VII of the National Health Act 1953, thereby altering their status under the Pharmaceutical Benefits Scheme. This declaration impacts entities and individuals involved in the prescription, supply, and reimbursement of these medications, as well as pharmaceutical companies that manufacture or distribute these drugs within Australia. The application of this legislation is nationwide, governed under the Commonwealth of Australia, and it affects the entire pharmaceutical industry by excluding the specified medications from the benefits previously provided under the Act. No specific exclusions, exemptions, or thresholds are mentioned in this declaration, and any further application or restrictions are potentially managed through subordinate instruments.

Key Provisions

The key provisions of this legislation, under the National Health Act 1953, involve the cessation of certain drugs and medicinal preparations from being covered under Part VII of the Act. Section 85(2AA) mandates that a declaration can be made to exclude specific pharmaceutical items from the Pharmaceutical Benefits Scheme (PBS). In this instance, the Assistant Secretary, Joan Corbett, has made a declaration (subsection 85(2AB)) based on advice from the Pharmaceutical Benefits Advisory Committee, as per subsection 85(2AA) of the National Health Act 1953. This declaration, which commenced on 1 December 2004, specifically removes the listed drugs and medicinal preparations from the PBS, as detailed in the Schedule. The obligations and requirements imposed by this legislation primarily involve the decision-making process leading to the declaration. The Assistant Secretary, acting as the delegate of the Minister for Health and Ageing, must obtain advice from the Pharmaceutical Benefits Advisory Committee before making the declaration. This ensures that the decision is informed by expert pharmaceutical advice and considers the implications of removing these items from the PBS. Once the advice is obtained, the declaration is made under subsection 85(2AA) and is effective from the specified commencement date. Failure to comply with the provisions of the National Health Act 1953, including the declaration process, can lead to legal consequences. While the specific penalties are not detailed in this excerpt, breaches of the Act can generally result in civil or criminal penalties, depending on the nature and severity of the breach. Civil penalties may include fines, while criminal penalties could involve imprisonment. The exact penalties would be determined based on the specific provisions of the Act and the circumstances of the breach.